米兰系统在囊性唾液腺病变细胞病理中的应用
该研究回顾性分析约翰霍普金斯医院19年间178例囊性唾液腺细针穿刺标本,应用米兰报告系统(MSRSGC)分类并计算恶性肿瘤风险(ROM)和肿瘤风险(RON)。结果显示SFM类别ROM为100%,SUMP为50%,AUS为29.4%,非诊断性为22.2%,非肿瘤性为19%。应用MSRSGC有助于避免非肿瘤性病变的不必要手术。
要点
- 囊性唾液腺FNA应用MSRSGC可提高诊断规范性并指导临床管理。
- SFM类别ROM达100%,SUMP为50%,AUS为29.4%,需警惕恶性可能。
- 标本不足可能增加AUS诊断,应关注取材质量。
核心结论
- 应用MSRSGC对囊性唾液腺病变进行分类可改善患者管理,避免非肿瘤性病变的不必要手术。
- ROM在SFM类别最高(100%),其次为SUMP、AUS、非诊断性和非肿瘤性类别。
- 标本不足可能增加AUS的诊断。
研究设计与样本
- 回顾性研究,检索约翰霍普金斯医院2000-2018年共19年的囊性唾液腺FNA标本。
- 共纳入178例病例(96例男性,82例女性),平均年龄53岁(范围4-90岁)。
- 记录患者人口学特征、细胞形态学特征及临床和手术随访资料,并应用MSRSGC分类。
- 计算每个类别的恶性肿瘤风险(ROM)和肿瘤风险(RON)。
主要发现
- MSRSGC分类结果:非诊断性52例(29.2%),非肿瘤性80例(44.9%),AUS 35例(19.7%),良性肿瘤3例(1.7%),SUMP 3例(1.7%),SFM 4例(2.2%),恶性1例(0.6%)。
- 有手术随访的病例中,非诊断性类别RON为33.3%(3/9),ROM为22.2%(2/9)。
- 非肿瘤性类别RON为42.9%(9/21),ROM为19%(4/21);AUS类别RON为76.5%(13/17),ROM为29.4%(5/17)。
- SUMP类别RON为100.0%(2/2),ROM为50.0%(1/2);SFM类别RON和ROM均为100%(2/2)。
临床怎么用
- 对囊性唾液腺FNA应用MSRSGC分类,有助于识别非肿瘤性病变,避免不必要的手术。
- 对于AUS、SUMP和SFM类别,应结合临床和影像学谨慎评估恶性风险。
- 注意标本取材质量,减少因标本不足导致的AUS诊断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cystic salivary gland lesions present diagnostic challenges on fine-needle aspiration (FNA) specimens that are related to sampling limitations and a broad differential diagnosis. This study evaluated the benefit of applying the Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) to a series of cystic salivary gland lesions. METHODS: The pathology archives at the Johns Hopkins Hospital were searched to identify cystic salivary gland FNA specimens over a 19-year period (2000-2018). Patient demographics, cytomorphologic features, and clinical and surgical follow-up were recorded. The MSRSGC was applied to the cases. The risk of malignancy (ROM) and the risk of neoplasia (RON) were calculated for each category. RESULTS: One hundred seventy-eight cases were identified (96 males and 82 females) with a mean age of 53 years (range, 4-90 years). After the MSRSGC was applied, there were 52 nondiagnostic cases (29.2%), 80 nonneoplastic cases (44.9%), 35 cases of atypia of undetermined significance (AUS; 19.7%), 3 benign neoplasms (1.7%), 3 salivary gland neoplasms of uncertain malignant potential (SUMP; 1.7%), 4 cases suspicious for malignancy (SFM; 2.2%), and 1 malignant case (0.6%). One hundred fifty-six of the 178 patients (87.6%) had follow-up data available. The RON and ROM values for cases with surgical follow-up were 33.3% (3 of 9) and 22.2% (2 of 9) for the nondiagnostic category, 42.9% (9 of 21) and 19% (4 of 21) for the nonneoplastic category, 76.5% (13 of 17) and 29.4% (5 of 17) for the AUS category, 100.0% (2 of 2) and 50.0% (1 of 2) for the SUMP category, and 100% (2 of 2) and 100% (2 of 2) for the SFM category, respectively. CONCLUSIONS: Applying the MSRSGC to cystic salivary gland lesions improves patient management by preventing unnecessary surgery for nonneoplastic conditions. The ROM was highest in the SFM category (100%), which was followed by the SUMP, AUS, nondiagnostic, and nonneoplastic categories. Less than adequate specimens may increase the diagnosis of AUS.
引用
- Maleki Z, Allison DB, Butcher M, et al. Application of the Milan System for Reporting Salivary Gland Cytopathology to cystic salivary gland lesions. Cancer Cytopathol. 2020. PMID: 33002347. doi:10.1002/cncy.22363
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。